Dcf Advisers, LLC Lensar, Inc. Transaction History

Dcf Advisers, LLC

$197 Million
Q1 2024

A detailed history of Dcf Advisers, LLC transactions in Lensar, Inc. stock. As of the latest transaction made, Dcf Advisers, LLC holds 238,234 shares of LNSR stock, worth $1.07 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares

238,234

Previous 240,534 0.96%

Holding current value

$1.07 Million

Previous $844,000 4.15%

% of portfolio

0.41%

Previous 0.47%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.25 - $5.0 $7,475 - $11,500	-2,300 Reduced 0.96%	238,234 $809,000
Q4 2023 Feb 13, 2024	SELL	$2.01 - $3.51 $84,424 - $147,427	-42,002 Reduced 14.87%	240,534 $844,000
Q3 2023 Nov 13, 2023	SELL	$3.02 - $4.45 $21,979 - $32,387	-7,278 Reduced 2.51%	282,536 $873,000
Q2 2023 Aug 09, 2023	SELL	$2.3 - $4.34 $140,134 - $264,427	-60,928 Reduced 17.37%	289,814 $1.23 Million
Q1 2023 May 15, 2023	BUY	$2.19 - $3.27 $10,950 - $16,350	5,000 Added 1.45%	350,742 $873,000

Q4 2022 Feb 13, 2023	SELL	$2.7 - $4.88 $33,358 - $60,292	-12,355 Reduced 3.45%	345,742 $1.02 Million
Q3 2022 Nov 14, 2022	BUY	$4.94 - $7.0 $304,175 - $431,018	61,574 Added 20.77%	358,097 $1.99 Million
Q2 2022 Aug 11, 2022	BUY	$6.15 - $7.94 $58,425 - $75,430	9,500 Added 3.31%	296,523 $1.93 Million
Q1 2022 May 13, 2022	BUY	$5.8 - $8.2 $41,963 - $59,326	7,235 Added 2.59%	287,023 $2.12 Million
Q2 2021 Aug 13, 2021	BUY	$6.87 - $8.66 $188,670 - $237,829	27,463 Added 10.88%	279,788 $2.42 Million
Q1 2021 May 12, 2021	BUY	$6.28 - $9.56 $597,071 - $908,917	95,075 Added 60.46%	252,325 $1.83 Million
Q4 2020 Feb 12, 2021	BUY	$6.7 - $12.2 $1.05 Million - $1.92 Million	157,250 New	157,250 $1.14 Million

Others Institutions Holding LNSR

# of Institutions

Shares Held

4.84M

Call Options Held

1.5K

Put Options Held

19.4K

View Full List

About LENSAR, Inc.

Ticker LNSR
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 11,021,000
Market Cap $49.6M
Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in...

More about LNSR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.

Account